本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Enlivex Therapeutics Ltd.

1.07
-0.0250-2.29%
成交量:16.95萬
成交額:18.19萬
市值:2.53億
市盈率:0.04
高:1.09
開:1.07
低:1.06
收:1.09
52周最高:2.10
52周最低:0.6600
股本:2.37億
流通股本:2.35億
量比:0.07
換手率:0.07%
股息:- -
股息率:- -
每股收益(TTM):25.48
每股收益(LYR):25.48
淨資產收益率:126.17%
總資產收益率:-0.80%
市淨率:0.13
市盈率(LYR):0.04

資料載入中...

2026/03/25

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2026/03/13

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/12/30

SEC問詢函

Form CORRESP - Correspondence
2025/05/09

SEC問詢函

Form CORRESP - Correspondence
2025/05/01

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/11/14

超過5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/04/30

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/04/10

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/05/03

SEC問詢函

CORRESP [Cover] - Correspondence
2022/04/29

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/06/04

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2021/04/30

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/02/10

[補充]招股説明書

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2021/02/09

[補充]招股説明書

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2020/08/14

財報披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/05/18

財報披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/04/30

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2020/04/13

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/18

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/05

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]